{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:43:42Z","timestamp":1790664222828,"version":"4.1.0"},"reference-count":18,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma is characterized by relapse and progressive disease, despite initial response to chemoimmunotherapy. We conducted a systematic review and meta\u2010analysis to determine the efficacy of rituximab maintenance (RM) therapy in patients with mantle cell lymphoma. We searched PubMed, Embase and Cochrane Central Register of Controlled Trials from database inception through November 1, 2017. Only full\u2010text articles were included. Prespecified data elements were extracted from each trial. Outcomes of interest included progression\u2010free survival (PFS) and overall survival (OS). The overall effect was pooled using the Der Simonian\u2010Laird random effects model. Three randomized controlled trials and four observational studies met our inclusion criteria and were identified in the analyses. Six studies compared RM therapy to observation, and one compared RM therapy to interferon alfa. Meta\u2010analysis evaluating outcomes of patients treated after ASCT revealed that RM improved for both PFS (HR\u2009= 0.33, 95% CI\u2009= 0.23\u20100.49) and OS (HR of death\u2009= 0.35, 95% CI\u2009= 0.17\u20100.69). A second meta\u2010analysis of studies evaluating outcomes of patients who are ASCT\u2010ineligible treated with anthracycline\u2010based induction therapy revealed that RM improved PFS (HR\u2009= 0.38, 95% CI\u2009= 0.25\u20100.58). There is a paucity of data on the role of RM in ASCT\u2010ineligible patients and those with relapsed disease. Overall, RM therapy appears to improve PFS and OS in previously untreated patients with mantle cell lymphoma who undergo induction chemoimmunotherapy followed by ASCT.<\/jats:p>","DOI":"10.1002\/ajh.25226","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T07:15:13Z","timestamp":1532330113000},"page":"1220-1226","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta\u2010analysis"],"prefix":"10.1002","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-4128","authenticated-orcid":false,"given":"Talal","family":"Hilal","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology\/Oncology Mayo Clinic  Phoenix Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Evidence\u2010Based Practice Center Mayo Clinic  Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Almader\u2010Douglas","sequence":"additional","affiliation":[{"name":"Mayo Clinic Libraries, Mayo Clinic  Phoenix Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-3163","authenticated-orcid":false,"given":"Allison","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology\/Oncology Mayo Clinic  Phoenix Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig B.","family":"Reeder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology\/Oncology Mayo Clinic  Phoenix Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology\/Oncology Mayo Clinic  Phoenix Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24797"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5904"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.218"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.332"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv364"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.07.006"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2554"},{"issue":"2","key":"e_1_2_6_18_1","first-page":"205\u201020","article-title":"Maintenance rituximab improves survival in newly diagnosed mantle cell lymphoma patients: analysis of the Czech lymphoma study group","volume":"35","author":"Obr A","year":"2017","journal-title":"Hematol Oncol."},{"issue":"15","key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","article-title":"Two years rituximab maintenance vs. observation after first\u2010line treatment with bendamustine plus rituximab (B\u2010R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7\u20142008 MAINTAIN trial)","volume":"34","author":"Rummel MJ","year":"2016","journal-title":"J Clin Oncol."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25226","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T07:16:49Z","timestamp":1694935009000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,3]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/ajh.25226"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25226","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,3]]},"assertion":[{"value":"2018-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}